Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Dr. Lal PathLabs's Revenue for the
three
months ended in Jun. 2026 was ₹7,977 Mil. Dr. Lal PathLabs's average Accounts Receivable for the
three
months ended in Jun. 2026 was ₹1,107 Mil.
Hence, Dr. Lal PathLabs's Receivables Turnover for the
three
months ended in Jun. 2026 was 7.21.
Dr. Lal PathLabs (NSE:LALPATHLAB) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Dr. Lal PathLabs Receivables Turnover Related Terms
Dr. Lal PathLabs Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Dr. Lal PathLabs's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:LALPATHLAB vs TMO, DHR, NTRA: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Dr. Lal PathLabs's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr. Lal PathLabs Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Dr. Lal PathLabs's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Dr. Lal PathLabs's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dr. Lal PathLabs (NSE:LALPATHLAB) has a Receivables Turnover of 7.21 as of Jun. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dr. Lal PathLabs and its competitors. According to the industry distribution chart, Dr. Lal PathLabs ranks #3 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 1.5%.
Is Dr. Lal PathLabs' Receivables Turnover too high?
Dr. Lal PathLabs' current Receivables Turnover is 7.21. The Medical Diagnostics & Research industry median Receivables Turnover is 5.40. Dr. Lal PathLabs' value of 7.21 is 33.6% above this industry median. Based on the distribution chart, Dr. Lal PathLabs ranks #3 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Dr. Lal PathLabs has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Dr. Lal PathLabs' Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Dr. Lal PathLabs ranks #3 out of 202 companies for Receivables Turnover. This places Dr. Lal PathLabs in the top 2% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.40. Dr. Lal PathLabs' value of 7.21 is 33.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.40, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dr. Lal PathLabs's current Receivables Turnover of 7.21 is 33.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Dr. Lal PathLabs and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dr. Lal PathLabs's current Receivables Turnover is 7.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr. Lal PathLabs stock overvalued right now?
Based on GuruFocus' analysis, Dr. Lal PathLabs (NSE:LALPATHLAB) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,769.42, compared to a current price of ₹1,909.00 — trading 7.9% above its estimated fair value. The current Receivables Turnover is 7.21 and 33.6% above the Medical Diagnostics & Research industry median of 5.40. Dr. Lal PathLabs' overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Dr. Lal PathLabs (NSE:LALPATHLAB), the current Receivables Turnover is 7.21 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dr. Lal PathLabs (NSE:LALPATHLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Dr. Lal PathLabs stock appears to be overvalued.
The current stock price of ₹1,909.00 is trading 7.9% above its estimated GF Value™ of ₹1,769.42.
GuruFocus considers Dr. Lal PathLabs to be Fairly Valued.
Key valuation signals for NSE:LALPATHLAB:
Receivables Turnover: 7.21
GF Value™: ₹1,769.42 vs. price of ₹1,909.00 (7.9% above fair value)
Industry Position: 33.6% above the Medical Diagnostics & Research median (#3 of 202)
No single metric tells the full story. See the NSE:LALPATHLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dr. Lal PathLabs Ltd is a pathology lab based in India. It is involved in providing diagnostic services and other healthcare tests in the areas of pathology and radiology. The company operates laboratories for carrying out pathological diagnostic services in various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, and other pathological and radiological investigations. Its diagnostic services assist in preventing, monitoring, and treating diseases and improving health conditions. The company has business operations in India and other countries, of which maximum revenue is generated within India.
95GF Score
Get the complete analysis for NSE:LALPATHLAB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LALPATHLAB has been successfully added to your 
